Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $110.5 million, down from $126.6 million in Q4 2024, primarily due to decreased demand from two large customers [5] - Full fiscal year 2025 revenue was $467.9 million, compared to $566.9 million in fiscal year 2024, reflecting a significant decline [5] - Gross margin for Q4 2025 was 6.2%, and operating margin was negative 2.1%, compared to 7.2% and 1.0% respectively in Q4 2024 [5] - The net loss for Q4 2025 was $3.9 million or $0.36 per share, compared to a net loss of $2.0 million or $0.18 per share in Q4 2024 [8] - For the full fiscal year 2025, the net loss was $8.3 million or $0.77 per share, compared to a net loss of $2.8 million or $0.26 per share in fiscal year 2024 [8] Business Line Data and Key Metrics Changes - The company cut approximately 300 jobs in 2025, totaling an 800 headcount reduction for the fiscal year, to align costs with current demand [6] - Despite revenue reduction, gross margins increased year over year due to operational efficiencies and cost-saving initiatives [6] Market Data and Key Metrics Changes - The company reduced inventory by approximately $8 million or 7% year over year, reflecting strategic initiatives to align inventory with current revenue [10] - Total liabilities were reduced by $32.7 million or 14% from the previous year [10] Company Strategy and Development Direction - The company is focusing on expanding its manufacturing footprint in the U.S. and Vietnam, with plans to invest over $28 million in a new facility in Arkansas [17] - The strategy includes enhancing production capabilities and mitigating tariff impacts by diversifying manufacturing locations [19] - The company anticipates that by the end of fiscal 2026, approximately half of its manufacturing will occur in the U.S. and Vietnam [19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging year due to reduced demand and tariff uncertainties but expressed optimism about future growth driven by new programs and operational efficiencies [13][26] - The company is not providing forward-looking guidance due to uncertainties in product ramp-up timing [13] Other Important Information - Cash flow from operations was $18.9 million for fiscal year 2025, up from $13.8 million in fiscal year 2024, indicating two consecutive years of positive cash flow [11] - The company is investing selectively in production equipment and automation to prepare for growth [12] Q&A Session Summary Question: What is the range of sizes for the new wins in the quarter? - The new wins were predominantly around $5 million, with potential for a data processing contract to exceed $20 million [29] Question: How is the Vietnam medical device manufacturing capability being developed? - The company is certified to build medical products in Vietnam and expects to start a program in fiscal 2026, anticipating additional opportunities [32] Question: What is driving the increase in new program bids? - Cost reductions and improved global footprint have opened up opportunities, alongside pent-up demand for U.S. manufacturing [36][37] Question: Can you explain the reduction in accounts receivable? - The reduction was primarily due to decreased revenue and improved collection efforts, with no factoring involved [41][42] Question: What is the potential size of the manufacturing services contract with the data processor OEM? - The contract is expected to generate $20 million in revenue, which is significant due to its potential margin improvement [48][49] Question: How do you see Mexico operations growing in fiscal 2026? - Recent program wins are expected to drive growth in Mexico, leveraging the USMCA agreement for tariff mitigation [56] Question: What are the expectations for gross margin in fiscal 2026? - The company aims to improve gross margins and expects incremental gross margins of 15% to 20% as revenue increases [59][61]

Market Overview - Market participants began the trading week without a clear catalyst, resulting in flat trading with the Dow down 14 points (-0.03%) and the S&P 500 down 1 point (-0.02%) [1] - The Nasdaq saw a slight gain of +0.03%, while the small-cap Russell 2000 outperformed with a +0.35% increase [1] Homebuilders Confidence - Homebuilders Confidence for August decreased to 32, lower than the expected 34 and matching June's level, which is the lowest since December 2021 [2] - Homebuilders are increasing incentives for new home sales to a five-year high due to weak demand and elevated mortgage rates [2] Interest Rate Outlook - No interest rate cuts are expected from the Federal Reserve until at least September 17, with a projected cut of 25 basis points [3] - This potential cut would bring the Fed funds rate below 4% for the first time in 2.5 years [3] Upcoming Housing Data - Upcoming housing data includes Housing Starts and Building Permits for July, expected to be slightly lower at 1.30 million and 1.39 million, respectively [4] - Existing Home Sales are anticipated to improve to 4.0 million from 3.93 million reported last month [4] Earnings Results - Palo Alto Networks reported fiscal Q4 earnings of 95 cents per share, exceeding the consensus of 88 cents, with revenues of $2.54 billion surpassing expectations of $2.50 billion [5] - Following the positive earnings report, Palo Alto Networks shares jumped +7% [5] - Fabrinet also reported Q4 earnings of $2.65, beating consensus by a penny, with revenues of $909.7 million exceeding the expected $883.1 million [6] - Despite positive guidance, Fabrinet shares fell -1.5% after a year-to-date gain of +48% [6]

Financial Data and Key Metrics Changes - The company reported revenue of $1,030 million in Q2 2025, a 0.6% increase year over year, with nearly half of the revenue outperformance driven by foreign exchange [9][10] - Organic revenue declined by 0.5%, primarily due to a low single-digit decline in the DSA segment, partially offset by low single-digit increases in RMS and manufacturing segments [10][12] - The operating margin improved to 22.1%, an increase of 80 basis points year over year, reflecting cost savings from restructuring and better sales volume [10][11] Business Line Data and Key Metrics Changes - DSA segment revenue was $618 million, a 2.4% decrease year over year on an organic basis, driven by lower revenue for discovery services [13] - RMS revenue increased by 2.3% on an organic basis to $213.3 million, primarily driven by the timing of NHP shipments and higher revenue for research model services [21][22] - Manufacturing segment revenue was $200.8 million, a 2.9% increase on an organic basis, driven by growth in microbial solutions [25][26] Market Data and Key Metrics Changes - Revenue for small and mid-sized biotech clients improved slightly for the third consecutive quarter, while revenue for global biopharmaceutical clients remained below last year's level but improved sequentially [10][21] - The demand environment for global biopharmaceutical clients appears to be stabilizing, with proposal activity increasing both year over year and sequentially [15][50] - The academic and government client segments saw revenue increases despite potential NIH budget cuts, with only a minor impact observed [22] Company Strategy and Development Direction - The company is focused on expanding its NAMS portfolio and enhancing scientific capabilities to support biopharmaceutical companies in transitioning to alternative technologies [19][20] - A strategic review is underway to evaluate avenues for value creation, including portfolio and capital allocation strategies [28][29] - The company aims to generate over $175 million in cost savings this year, contributing to improved financial performance [11][44] Management's Comments on Operating Environment and Future Outlook - Management noted that the global biopharmaceutical demand trends appear to have bottomed and are beginning to slowly move upward [7] - The company raised its revenue and non-GAAP earnings per share guidance due to outperformance in Q2, reflecting a more favorable demand environment [12][33] - There is recognition of ongoing uncertainty in the healthcare landscape, but management remains optimistic about stabilization in demand [8][9] Other Important Information - The company experienced a slight decline in DSA backlog to $1.93 billion, with gross and net bookings improving at mid-single-digit rates year over year [14] - The non-GAAP tax rate increased to 22.7%, primarily due to stock-based compensation, but was more favorable than expected [40][41] - Free cash flow for Q2 was strong at $169.3 million, driven by higher earnings and improved working capital [42][43] Q&A Session Summary Question: Current demand environment and pharma's perspective - Management indicated that the demand situation is stabilizing for pharma, with some demand trends having bottomed [48] - Revenue and proposals are up, but cancellations have also increased, particularly for longer-term post-IND work [49][50] Question: Clarification on revenue guidance and book-to-bill ratio - Management stated that the current book-to-bill ratio is expected to remain in the range of 0.8 to 0.93, which does not require improvement to meet guidance [55] Question: CDMO performance and revenue impact - The CDMO revenue headwind is expected to be around $20 million due to the wind-down of a client relationship, with higher margins noted in the first half [62][63] Question: Backlog conversion and revenue support - Management believes the backlog is stable and robust, allowing for continued drawing from it to replace studies that slip or cancel [72][74] Question: Hiring confidence and future growth - Management expressed confidence in hiring to meet current demand, with improvements in the overall demand curve expected to support future growth [78][79] Question: Pricing stability and margin implications - Pricing in DSA remains stable, with mix favorability contributing positively to margins [82][84] Question: Cancellations in longer-term work - Cancellations are not expected to significantly impact margins, as the margin profile for different types of work is often comparable [86]